AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24666826 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's solution (3 ml/kg bolus without continuous infusion)
Number of subjects: 40
Study 22201291 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at a psychological support group
Number of subjects: 72
Study 22201291 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 72
Study 22201291 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological support group
Number of subjects: 72
Study 20019345 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making (SDM)
Number of subjects: 612
Study 17911444 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine (BRC) 2.5 mg/day and prednisone 10 mg/day
Number of subjects: 20
Study 17911444 — intervention group
Group type: COMPARATOR
Intervention: Prednisone 10 mg/day
Number of subjects: 20
Study 17029177 — intervention group
Group type: EXPERIMENTAL
Intervention: Early mobilization after aortic valve surgery
Number of subjects: 1200
Study 17029177 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiological evidence from controlled studies in patients undergoing AVR
Number of subjects: 1200
Study 12859700 — intervention group
Group type: EXPERIMENTAL
Intervention: bupropion SR 300 mg daily for 7 weeks
Number of subjects: 707
Study 12859700 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 707
Study 10510878 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimebutine maleate (oral treatment for three weeks)
Number of subjects: 63
Study 10510878 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal volunteers)
Number of subjects: 63
Study 8646710 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oral granisetron as a divided dose (1 hour prior to chemotherapy and 12 hours after the start of chemotherapy)
Number of subjects: 697
Study 8646710 — intervention group
Group type: COMPARATOR
Intervention: 2 mg oral granisetron as a single dose (1 hour prior to chemotherapy)
Number of subjects: 697
Study 2049964 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin 300 mg b.i.d.
Number of subjects: 60
Study 2049964 — intervention group
Group type: COMPARATOR
Intervention: Trimethoprim + Sulfamethoxazole (TMP 800 mg + SMX 160 mg), 1 tablet, b.i.d.
Number of subjects: 60
Study 6342408 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthokeratology (OK)
Number of subjects: 31
Study 6342408 — intervention group
Group type: COMPARATOR
Intervention: Conventional rigid contact lenses (Control)
Number of subjects: 31
Study 30621298 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant-based multivitamin/mineral and phytonutrient (PMP) supplementation for eight weeks
Number of subjects: 0
Study 30621298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28338507 — intervention group
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein
Number of subjects: 15
Study 28338507 — intervention group
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein + OK-432
Number of subjects: 15
Study 28338507 — intervention group
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein + poly-ICLC
Number of subjects: 15
Study 28338507 — intervention group
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 protein + OK-432 + poly-ICLC
Number of subjects: 15
Study 27449548 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Recommendation Tracking Form (MRTF)
Number of subjects: 482
Study 24496960 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine dosing algorithm (5 μg/kg(1.5)/h for neonates with PNA <10 days)
Number of subjects: 38
Study 24496960 — intervention group
Group type: COMPARATOR
Intervention: Traditional dosing (for older patients with PNA ≥10 days)
Number of subjects: 38
Study 21713599 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam
Number of subjects: 120
Study 21713599 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 120
Study 21713599 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 120
Study 19464028 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose continuous levalbuterol (LEV) 10 mg/hour
Number of subjects: 81
Study 19464028 — intervention group
Group type: COMPARATOR
Intervention: Racemic albuterol (RAC) 20 mg/hour
Number of subjects: 81
Study 17446290 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive handwashing intervention (handwashing after defecation, after cleaning infants, before preparing food, before eating, and before and after sex)
Number of subjects: 148
Study 17446290 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intensive handwashing intervention)
Number of subjects: 148
Study 15745448 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) game coupled with pharmacological analgesia
Number of subjects: 7
Study 15745448 — intervention group
Group type: COMPARATOR
Intervention: Pharmacological analgesia only
Number of subjects: 7
Study 12105816 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate supplementation (7.7 micromol zinc sulfate, 50 mg elemental zinc) for 90 days
Number of subjects: 28
Study 12105816 — intervention group
Group type: COMPARATOR
Intervention: Cornstarch placebo capsule for 90 days
Number of subjects: 28
Study 10188745 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise during the follicular phase (30 min at 75‐80% VO2max)
Number of subjects: 11
Study 10188745 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise during the luteal phase (30 min at 75‐80% VO2max)
Number of subjects: 11
Study 7582389 — intervention group
Group type: EXPERIMENTAL
Intervention: Xylitol (10% solution, infused intravenously over 2 hours)
Number of subjects: 5
Study 1710487 — intervention group
Group type: EXPERIMENTAL
Intervention: ProMACE-CytaBOM
Number of subjects: 193
Study 1710487 — intervention group
Group type: COMPARATOR
Intervention: ProMACE-MOPP
Number of subjects: 193
Study 6798826 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin
Number of subjects: 60
Study 6798826 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual nitroglycerin
Number of subjects: 60
Study 31418073 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation techniques implemented once a day for 30 minutes during 60 consecutive days in addition to routine care
Number of subjects: 80
Study 31418073 — intervention group
Group type: COMPARATOR
Intervention: Routine care only
Number of subjects: 80
Study 30650446 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (10 mg twice daily for 7 days, then 5 mg twice daily thereafter)
Number of subjects: 5365
Study 30650446 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/warfarin (1 mg/kg twice daily for ≥ 5 days, followed by warfarin)
Number of subjects: 5365
Study 30650446 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban (with anti-platelet therapy)
Number of subjects: 5365
Study 30650446 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/warfarin (with anti-platelet therapy)
Number of subjects: 5365
Study 28249792 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid (ALA) for 40 days after surgical decompression
Number of subjects: 64
Study 28249792 — intervention group
Group type: COMPARATOR
Intervention: Placebo after surgical decompression
Number of subjects: 64
Study 27212154 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable bioactive glass
Number of subjects: 58
Study 27212154 — intervention group
Group type: COMPARATOR
Intervention: Hydroxyapatite bioceramics
Number of subjects: 58
Study 23499806 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion at a rate of 1 pmol/kg/min for 4h
Number of subjects: 6
Study 23499806 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 6
Study 21163569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical BCG (81 mg)
Number of subjects: 99
Study 21163569 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical BCG (27 mg)
Number of subjects: 99
Study 21163569 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG (27 mg) with interferon alpha (IFN-α)
Number of subjects: 99
Study 18297268 — intervention group
Group type: EXPERIMENTAL
Intervention: eMPC group (n = 25) using the laptop‐based algorithm
Number of subjects: 50
Study 18297268 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 25) treated by an implemented insulin algorithm
Number of subjects: 50
Study 18297268 — intervention group
Group type: EXPERIMENTAL
Intervention: eMPC group
Number of subjects: 50
Study 18297268 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50
Study 16595318 — intervention group
Group type: EXPERIMENTAL
Intervention: Category-based ethnicity screening question
Number of subjects: 4559
Study 16595318 — intervention group
Group type: EXPERIMENTAL
Intervention: Binary plus open-ended ethnicity screening question
Number of subjects: 4559
Study 12702522 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 20 mg/m(2) on days 1 and 8 (group 1)
Number of subjects: 60
Study 12702522 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 30 mg/m(2) on day 1 and 10 mg/m(2) on day 8 (group 2)
Number of subjects: 60
Study 12702522 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinorelbine 40 mg/m(2) on day 1 (group 3)
Number of subjects: 60
Study 10898445 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitor
Number of subjects: 24
Study 10898445 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study 8935815 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 200
Study 8935815 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 200
Study 1576853 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week in-hospital physical training program
Number of subjects: 22
Study 1576853 — intervention group
Group type: COMPARATOR
Intervention: No training (untrained group)
Number of subjects: 22
Study 3921518 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) load (920 cal)
Number of subjects: 18
Study 3921518 — intervention group
Group type: COMPARATOR
Intervention: Liquid placebo
Number of subjects: 18
Study 31305131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus letrozole
Number of subjects: 0
Study 31305131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus fulvestrant
Number of subjects: 0
Study 31305131 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus tamoxifen/nonsteroidal aromatase inhibitor with ovarian function suppression
Number of subjects: 0
Study 29477448 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol (110 μg) plus glycopyrronium (50 μg) once per day for 14 days
Number of subjects: 62
Study 29477448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 27383664 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic-guided dosing
Number of subjects: 1010
Study 27383664 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically guided dosing
Number of subjects: 1010
Study 27383664 — intervention group
Group type: COMPARATOR
Intervention: EU-PACT strategy
Number of subjects: 1010
Study 27383664 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose group
Number of subjects: 1010
Study 24096105 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous T‐CPR
Number of subjects: 95
Study 24096105 — intervention group
Group type: COMPARATOR
Intervention: Standard T‐CPR
Number of subjects: 95
Study 22534813 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous lysis of epidural adhesions
Number of subjects: 92
Study 22534813 — intervention group
Group type: COMPARATOR
Intervention: Injection dexamethasone only (Control)
Number of subjects: 92
Study 19962699 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual postpartum care plus telephone‐based peer support
Number of subjects: 701
Study 19962699 — intervention group
Group type: COMPARATOR
Intervention: Usual postpartum care
Number of subjects: 701
Study 18525027 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 or 80 mg/day
Number of subjects: 26
Study 18525027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 18525027 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (combined with interferon beta‐1a)
Number of subjects: 26
Study 18525027 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 26
Study 17097736 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean follow-up IOP
Number of subjects: 255
Study 17097736 — intervention group
Group type: EXPERIMENTAL
Intervention: IOP fluctuation
Number of subjects: 255
Study 17097736 — intervention group
Group type: COMPARATOR
Intervention: Glaucoma progression
Number of subjects: 255
Study 15457423 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg for 7 days followed by 21 additional days of fondaparinux
Number of subjects: 656
Study 15457423 — intervention group
Group type: COMPARATOR
Intervention: Placebo (short-term prophylaxis)
Number of subjects: 656
Study 11421879 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 250 mg b.d. (PAC 250)
Number of subjects: 154
Study 11421879 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg b.d. (PAC 500)
Number of subjects: 154
Study 11421879 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 154
Study 10423636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1) infusion for 24 hours at a mean dosage of 16 +/- 3 ng/kg/min (range, 10-20 ng/kg/min)
Number of subjects: 30
Study 10423636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1) infusion
Number of subjects: 30
Study 10423636 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Group I)
Number of subjects: 30
Study 10423636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous prostaglandin E1 (PGE1) during PTCA
Number of subjects: 30
Study 8275922 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 65
Study 8275922 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 65
Study 8275922 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment using MADRS, HARD diagram, checklist for somatic symptoms and side-effects
Number of subjects: 65
Study 8275922 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment using Hamilton Anxiety Rating Scale (HARS) and sleep questionnaire
Number of subjects: 65
Study 8275922 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Global Impression (CGI), Therapeutic Index (TI), Tolerance Global Impression
Number of subjects: 65
Study 2882768 — intervention group
Group type: EXPERIMENTAL
Intervention: Edrophonium 0.5 mg kg‐1
Number of subjects: 20
Study 2882768 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg kg‐1
Number of subjects: 20
Study 30019244 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 group (weaned at 7 days, fed formulated semi‐solid broiler goat concentrate diet)
Number of subjects: 14
Study 30019244 — intervention group
Group type: EXPERIMENTAL
Intervention: T2 group
Number of subjects: 14
Study 29675114 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-Assisted Gait Training (RAGT)
Number of subjects: 19
Study 29675114 — intervention group
Group type: COMPARATOR
Intervention: Therapist-Assisted Gait Training (TAGT)
Number of subjects: 19
Study 27438317 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate (3.5 g/d)
Number of subjects: 257
Study 27438317 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 257
Study 24283388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement containing lycopene, β-carotene, and Lactobacillus johnsonii
Number of subjects: 60
Study 24283388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24283388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional supplement
Number of subjects: 60
Study 21899713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodesoxycholic acid (UDCA) 10 mg/kg orally per day for 24 months
Number of subjects: 71
Study 21899713 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablet for 24 months
Number of subjects: 71
Study 21899713 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodesoxycholic acid (UDCA)
Number of subjects: 71
Study 21899713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 19023223 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact anaesthesia
Number of subjects: 120
Study 19023223 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar anaesthesia
Number of subjects: 120
Study 17228035 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanita TBF‐305 body fat analyzer (%FM(T‐Man))
Number of subjects: 38
Study 17228035 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanita TBF‐305 body fat analyzer (%FM(T‐Jebb))
Number of subjects: 38
Study 17228035 — intervention group
Group type: EXPERIMENTAL
Intervention: Four-compartment model (%FM(4C))
Number of subjects: 38
Study 15746106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (20 mg daily)
Number of subjects: 5408
Study 15746106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5408
Study 15746106 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 5408
Study 12197590 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instructional intervention based on the Transtheoretical Model (TM)
Number of subjects: 0
Study 12197590 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 12197590 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-instructional intervention based on the TM
Number of subjects: 0
Study 9808231 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional dairy products (34 g lactose/d)
Number of subjects: 62
Study 9808231 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactose-hydrolyzed dairy products (2 g lactose/d)
Number of subjects: 62
Study 8074079 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplements
Number of subjects: 56
Study 8074079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 2687426 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 483
Study 2687426 — intervention group
Group type: EXPERIMENTAL
Intervention: Having more siblings
Number of subjects: 483
Study 2687426 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal smoking and low social class
Number of subjects: 483
Study 2687426 — intervention group
Group type: EXPERIMENTAL
Intervention: House dust antigen
Number of subjects: 483
Study 2687426 — intervention group
Group type: EXPERIMENTAL
Intervention: Season of birth (Autumn)
Number of subjects: 483
Study 31875256 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination of potentially irritating beverages (PIBs)
Number of subjects: 0
Study 31875256 — intervention group
Group type: COMPARATOR
Intervention: Diet/exercise recommendations (Control)
Number of subjects: 0
Study 31507001 — intervention group
Group type: EXPERIMENTAL
Intervention: iHEART intervention with AliveCor KardiaMobile ECG monitor
Number of subjects: 238
Study 31507001 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 238
Study 31507001 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrence during the first month after ablation
Number of subjects: 238
Study 28643661 — intervention group
Group type: EXPERIMENTAL
Intervention: General or spinal anaesthesia
Number of subjects: 100
Study 28643661 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthesia
Number of subjects: 100
Study 25423308 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual-thrust manipulation (MTM)
Number of subjects: 107
Study 25423308 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical-assisted manipulation (MAM)
Number of subjects: 107
Study 25423308 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (UMC)
Number of subjects: 107
Study 24012035 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe calcification
Number of subjects: 755
Study 21377689 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of a watchful invisible person ('Princess Alice')
Number of subjects: 0
Study 21377689 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation by a real adult
Number of subjects: 0
Study 21377689 — intervention group
Group type: COMPARATOR
Intervention: Unsupervised condition
Number of subjects: 0
Study 19139780 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose folic acid (5 mg/day)
Number of subjects: 246
Study 19139780 — intervention group
Group type: COMPARATOR
Intervention: Low dose folic acid (0.5 mg/day)
Number of subjects: 246
Study 17716344 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteopathy (OG)
Number of subjects: 39
Study 17716344 — intervention group
Group type: COMPARATOR
Intervention: Standard Care (SCG)
Number of subjects: 39
Study 15215111 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL5788 at 500 mg
Number of subjects: 16
Study 15215111 — intervention group
Group type: EXPERIMENTAL
Intervention: BAL5788 at 750 mg
Number of subjects: 16
Study 15215111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15607398 — intervention group
Group type: EXPERIMENTAL
Intervention: RSD-2 (2 mg/kg followed by 3 mg/kg)
Number of subjects: 56
Study 11303205 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate 20 mg
Number of subjects: 34
Study 11303205 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate 40 mg
Number of subjects: 34
Study 11303205 — intervention group
Group type: COMPARATOR
Intervention: Vaginal examination only
Number of subjects: 34
Study 9278949 — intervention group
Group type: EXPERIMENTAL
Intervention: Apomorphine (APO; 0.75 mg sc)
Number of subjects: 24
Study 9278949 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 24
Study 8354726 — intervention group
Group type: EXPERIMENTAL
Intervention: Topically-applied light-cured resin
Number of subjects: 10
Study 8354726 — intervention group
Group type: COMPARATOR
Intervention: Placebo, sham light-cured
Number of subjects: 10
Study 3016226 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metoclopramide (0.5 mg/kg/24 h)
Number of subjects: 0
Study 3016226 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid alginic acid‐antacid compound
Number of subjects: 0
Study 27783535 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive prime (portraying older individuals as an asset)
Number of subjects: 51